Literature DB >> 25183285

The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading.

O Pozdnyakova1, S Rodig1, S Bhandarkar2, K Wu2, J Thiele3, R Hasserjian4.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25183285     DOI： 10.1038/leu.2014.262

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.

Authors:  Umberto Gianelli; Claudia Vener; Anna Bossi; Ivan Cortinovis; Alessandra Iurlo; Nicola S Fracchiolla; Federica Savi; Alessia Moro; Federica Grifoni; Chiara De Philippis; Tommaso Radice; Silvano Bosari; Giorgio Lambertenghi Deliliers; Agostino Cortelezzi
Journal:  Mod Pathol       Date:  2012-05-25       Impact factor: 7.842

2.  Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.

Authors:  J T Ellis; P Peterson; S A Geller; H Rappaport
Journal:  Semin Hematol       Date:  1986-04       Impact factor: 3.851

3.  Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.

Authors:  Bridget S Wilkins; Deepti Radia; Claire Woodley; Sarah El Farhi; Clodagh Keohane; Claire N Harrison
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

4.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Authors:  Ayalew Tefferi; Francisco Cervantes; Ruben Mesa; Francesco Passamonti; Srdan Verstovsek; Alessandro M Vannucchi; Jason Gotlib; Brigitte Dupriez; Animesh Pardanani; Claire Harrison; Ronald Hoffman; Heinz Gisslinger; Nicolaus Kröger; Juergen Thiele; Tiziano Barbui; Giovanni Barosi
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

5.  Central pathology review for phase III clinical trials: the enabling effect of virtual microscopy.

Authors:  Pawel Mroz; Anil V Parwani; Piotr Kulesza
Journal:  Arch Pathol Lab Med       Date:  2013-04       Impact factor: 5.534

6.  Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.

Authors:  J Thiele; H M Kvasnicka
Journal:  Ann Hematol       Date:  2006-01-19       Impact factor: 3.673

7.  Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.

Authors:  Cecilia Arana Yi; Ghayathri Jeyakumar; Pedro Medina; Jorge Cortes; Sherry Pierce; Carlos Bueso-Ramos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-11-13       Impact factor: 3.156

8.  Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.

Authors:  J Thiele; H M Kvasnicka; A Schmitt-Graeff; V Diehl
Journal:  Leuk Lymphoma       Date:  2003-06

9.  Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.

Authors:  Claudia Vener; Nicola Stefano Fracchiolla; Umberto Gianelli; Rossella Calori; Franca Radaelli; Alessandra Iurlo; Sabrina Caberlon; Giancarla Gerli; Leonardo Boiocchi; Giorgio Lambertenghi Deliliers
Journal:  Blood       Date:  2007-11-20       Impact factor: 22.113

10.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528
View more
  5 in total

1.  JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Waihay J Wong; Robert P Hasserjian; Geraldine S Pinkus; Lawrence J Breyfogle; Ann Mullally; Olga Pozdnyakova
Journal:  Haematologica       Date:  2017-11-16       Impact factor: 9.941

2.  Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.

Authors:  Jeremy St John Thomas; Elena Provenzano; Louise Hiller; Janet Dunn; Clare Blenkinsop; Louise Grybowicz; Anne-Laure Vallier; Ioannis Gounaris; Jean Abraham; Luke Hughes-Davies; Karen McAdam; Stephen Chan; Rizvana Ahmad; Tamas Hickish; Stephen Houston; Daniel Rea; Carlos Caldas; John Ms Bartlett; David Allan Cameron; Richard Laurence Hayward; Helena Margaret Earl
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

Review 3.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

Review 4.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

5.  Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Authors:  Hans Michael Kvasnicka; Jürgen Thiele; Carlos E Bueso-Ramos; William Sun; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.